Medical devices, healthcare technology and the business of care
PMA approval · P240035

ETHIZIA

ETHICON, Inc. · Decision date Dec 15, 2025

FDA DECISIONP240035

What did the FDA approve?

FDA records P240035 as an original PMA application. The recorded decision is approval, dated Dec 15, 2025.

FDA approval order statement

Approval for ETHIZIA indicated for use in adult patients with a body weight of greater than or equal to 25kg as an adjunct to hemostasis in open liver surgery for minimal, mild, or moderate bleeding sites when control of bleeding by standard surgical techniques (such as suture, ligature or cautery) is ineffective or impractical.
Regulatory pathway
Original PMA
Clinical specialty
General, Plastic Surgery
Decision date
Dec 15, 2025

FDA source record

Regulatory record facts

Identifier
P240035
Regulatory pathway
Premarket approval application
Applicant
ETHICON, Inc.
Product code
SGV
Decision code
APPR
Decision date
Dec 15, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Agent, absorbable hemostatic, collagen with polymeric additives.

Applicant
ETHICON, Inc.
Product code
SGV
FDA device class
3

The approval statement above describes the scope recorded for this original decision. Later supplements may change the device or its indications.

FDA decision timeline

  1. P240035 received

    Application receipt date recorded by FDA.

  2. P240035 · FDA decision

    APPR

  3. P240035/S001 · Related supplement

    ETHIZIA Hemostatic Patch

  4. P240035/S003 · Related supplement

    ETHIZIA Hemostatic Patch

  5. P240035/S006 · Related supplement

    ETHIZIA Hemostatic Patch

  6. P240035/S005 · Related supplement

    ETHIZIA Hemostatic Patch

  7. P240035/S002 · Related supplement

    ETHIZIA Hemostatic Patch

  8. P240035/S004 · Related supplement

    ETHIZIA Hemostatic Patch

Timeline entries are records held by MedtechLedger for P240035. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P240035

Product / regulatory recordCompanyPathwayDecision dateSource
ETHICON, Inc.PMA supplementJan 22, 2026FDA
ETHICON, Inc.PMA supplementJan 28, 2026FDA
ETHICON, Inc.PMA supplementFeb 24, 2026FDA
ETHICON, Inc.PMA supplementFeb 26, 2026FDA
ETHICON, Inc.PMA supplementJun 25, 2026FDA
ETHICON, Inc.PMA supplementAug 27, 2026FDA

Explore the linked device profile

Regulatory context

An original PMA is a premarket approval application. The recorded approval scope is described in FDA’s order and supporting documents.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

ETHICON, Inc.

Headquarters
Not reported
Brand website
ethicon.com
FDA applicant address
1000 Rte. 202, Raritan, NJ, 08869

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records